Bionano Stock Retains Its ‘Strong Buy’ Status

If Bionano’s (BNGO) optical genome mapping (OGM) system Saphyr is to gain mainstream adoption, it has to show its performance improves on standard of care (SOC) methods. So far, it appears to be doing...

New Developments Bode Well for Bionano Stock, Says Analyst

This time last year, shares of Bionano Genomics (BNGO) were in the midst of one almighty tear, as the market seized upon the opportunity of its optical genome mapping (OGM) system Saphyr to disrupt th...